The NeuroMotor Pen™ Platform

Class 2 FDA authorised

Enabling more accurate, objective and automated neurological assessments

With state-of-the-art sensing technologies, proprietary algorithms and applied AI

Transforming handwriting and drawing into a powerful window into human neurophysiology

Why It Matters

We live in an aging society with a decline in brain health:

It is estimated that there are 7 – 14 million people with mild cognitive impairment, who are at risk of developing a form of dementia. Multiple studies report that 90% go undiagnosed.

There are 10 million people with tremor at risk of developing Parkinson’s Disease or Lewy Body Dementia.

These individuals are usually aware of subtle signs and symptoms and often worry because they can't get a clear explanation for them. They are in need of a test, but frequently do not see a doctor. Consequently, by the time symptoms have worsened and a doctor’s visit becomes urgent and they receive a diagnosis, their syptoms have progressed and options for early intervention have been missed.

Early detection and diagnostic confirmation when intervention matters most is crucial for increased longevity with improved quality of life.

How Does It Work?

Handwriting and drawing are among the most complex motor tasks humans are capable of performing. By capturing micro-scale movement dynamics, the NMP enables precise quantification of motor and cognitive symptoms, characterization of motor variability, sensorimotor integration, and pathophysiological signatures.

A multi-disciplinary approach was taken with involvement of clinical and scientific teams to derive robust biomarkers. The data sets underlying the validation were collected over a 10-year period.

The implementation is straightforward, but nevertheless groundbreaking:

Implementing assessments derived from current best practice, but with more objective and accurate symptom quantification.

Proprietary algorithms enable the derivation of digital biomarkers for precise quantification of neuromotor (movement) and neurocognitive symptoms.

These biomarkers are associated with commonly used clinical rating scales in neurological and psychiatric disorders.

The automated analyses improve objectivity and accuracy over clinical observation while reducing assessment time.

The benefits

More objective and accurate symptom rating enables better symptom tracking and diagnostic decision support.

The assessments can be democratised to non-experts within the health system, which will streamline pathways smoothing referrals from primary care to specialist clinics.